Study Summary
The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
Want to learn more about this trial?
Request More InfoInterventions
IMA201 ProductBIOLOGICAL
The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
IMADetect®DIAGNOSTIC_TEST
IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | United States |
| University of Texas MD Anderson Cancer Center | Houston | Texas | United States |
| Universitätsklinikum Bonn, Venusberg-Campus 1 | Bonn | North Rhine-Westphalia | Germany |
| Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74 | Dresden | Saxony | Germany |
| Universitätsklinikum Hamburg-Eppendorf | Hamburg | Germany |